| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002787 | American Journal of Ophthalmology | 2011 | 7 Pages |
Abstract
The introduction of anti-VEGF intravitreal injections has offered remarkable clinical benefits for patients with neovascular AMD, but these benefits have come at the cost of an increased financial burden of providing care for these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Shelley Day, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, Frank A. Sloan,